{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:22:38Z","timestamp":1793726558197,"version":"4.6.1"},"reference-count":119,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":368,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011724","name":"Muscular Dystrophy UK","doi-asserted-by":"publisher","award":["22GRO-PG36-0552"],"award-info":[{"award-number":["22GRO-PG36-0552"]}],"id":[{"id":"10.13039\/100011724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X008029\/1"],"award-info":[{"award-number":["MR\/X008029\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/Y008405\/1"],"award-info":[{"award-number":["MR\/Y008405\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003784","name":"Great Ormond Street Hospital for Children","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"University College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012357","name":"LifeArc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ymthe.2025.04.038","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T20:38:25Z","timestamp":1745959105000},"page":"2689-2704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4429-0586","authenticated-orcid":false,"given":"Laia","family":"Torres-Masjoan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Aguti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9102-5232","authenticated-orcid":false,"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.04.038_bib1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.04.038_bib2","article-title":"FDA approves fomivirsen, famciclovir, and Thalidomide","volume":"5","author":"Highleyman","year":"1998","journal-title":"Food Drug Adm. BETA: Bull. Exp. treatments AIDS: a Publ. San Francisco AIDS Found."},{"key":"10.1016\/j.ymthe.2025.04.038_bib3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40265-013-0042-2","article-title":"Mipomersen Sodium: First Global Approval","volume":"73","author":"Hair","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2025.04.038_bib4","first-page":"717","article-title":"Clearance kinetics, biodistribution, and organ saturability of phosphorothioate oligodeoxynucleotides in mice","volume":"149","author":"Rifai","year":"1996","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2025.04.038_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.038_bib6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2025.04.038_bib7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: The protein product of the duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.04.038_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2025.04.038_bib9","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3233\/JND-230185","article-title":"Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy","volume":"11","author":"Zaidman","year":"2024","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.04.038_bib10","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.04.038_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.addr.2015.05.008","article-title":"Exon skipping therapy for Duchenne muscular dystrophy","volume":"87","author":"Kole","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2025.04.038_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14712598.2017.1271872","article-title":"Exon skipping: a first in class strategy for Duchenne muscular dystrophy","volume":"17","author":"Niks","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.038_bib13","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41434-021-00222-4","article-title":"Genome editing for Duchenne muscular dystrophy: a glimpse of the future?","volume":"28","author":"Kupatt","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.038_bib14","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2004840117","article-title":"Toward the correction of muscular dystrophy by gene editing","volume":"118","author":"Olson","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.04.038_bib15","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.3390\/ijms23031832","article-title":"CRISPR Therapeutics for Duchenne Muscular Dystrophy","volume":"23","author":"Erkut","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.04.038_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122003","article-title":"Role of CRISPR\/Cas9 in the treatment of Duchenne muscular dystrophy and its delivery strategies","volume":"330","author":"Agrawal","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.ymthe.2025.04.038_bib17","first-page":"43","article-title":"Read-through approach for stop mutations in Duchenne muscular dystrophy. An update","volume":"40","author":"Politano","year":"2021","journal-title":"Acta Myol."},{"key":"10.1016\/j.ymthe.2025.04.038_bib18","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1089\/hum.2006.061","article-title":"Comparative Analysis of Antisense Oligonucleotide Sequences for Targeted Skipping of Exon 51 During Dystrophin Pre-mRNA Splicing in Human Muscle","volume":"18","author":"Arechavala-Gomeza","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.038_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2025.04.038_bib20","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/mt.2008.287","article-title":"Design of Phosphorodiamidate Morpholino Oligomers (PMOs) for the Induction of Exon Skipping of the Human DMD Gene","volume":"17","author":"Popplewell","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.038_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: First Approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2025.04.038_bib22","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First Approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2025.04.038_bib23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2025.04.038_bib24","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2025.04.038_bib25","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3233\/JND-210643","article-title":"Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial","volume":"8","author":"McDonald","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.04.038_bib26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/JND-210665","article-title":"A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment","volume":"9","author":"Mitelman","year":"2022","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.04.038_bib27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/mus.27662","article-title":"Delays in pulmonary decline in eteplirsen-treated patients with Duchenne muscular dystrophy","volume":"66","author":"Iff","year":"2022","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2025.04.038_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/mus.28075","article-title":"Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls","volume":"70","author":"Iff","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2025.04.038_bib29","series-title":"Poster Presented at the 27th International Hybrid Annual Congress of the World Muscle Society","article-title":"Interim Analysis of EVOLVE: A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice","author":"Ricchetti-Masterson","year":"2022"},{"key":"10.1016\/j.ymthe.2025.04.038_bib30","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2025.04.038_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1\/2 Trial","volume":"32","author":"Servais","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2025.04.038_bib32","series-title":"Poster P.283, World Muscle Soc. Virtual Congress","article-title":"Long-term Safety and Efficacy of Golodirsen in Male Patients With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping","author":"Muntoni","year":"2020"},{"key":"10.1016\/j.ymthe.2025.04.038_bib33","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.omtn.2018.09.017","article-title":"NS-065\/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy","volume":"13","author":"Watanabe","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.04.038_bib34","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2025.04.038_bib35","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3233\/JND-220811","article-title":"Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy","volume":"9","author":"Clemens","year":"2022","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.04.038_bib36","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3233\/JND-221656","article-title":"Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study","volume":"10","author":"Clemens","year":"2023","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.04.038_bib37","author":"Pharma"},{"key":"10.1016\/j.ymthe.2025.04.038_bib38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/mus.27347","article-title":"Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial","volume":"64","author":"Wagner","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2025.04.038_bib40","series-title":"Poster P.132, 27th International Hybrid Annual Congress of the World Muscle Society","article-title":"Casimersen in Patients With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping: Interim Results From the Phase 3 ESSENCE Trial","author":"Iannaccone","year":"2022"},{"key":"10.1016\/j.ymthe.2025.04.038_bib41","series-title":"Poster P.288, World Muscle Soc. Virtual Congress","article-title":"Casimersen Treatment in Patients With Duchenne Muscular Dystrophy: Safety, Tolerability, and Pharmacokinetics Over 144 Weeks of Treatment","author":"Wagner","year":"2020"},{"key":"10.1016\/j.ymthe.2025.04.038_bib42","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamaneurol.2013.4908","article-title":"Biochemical Characterization of Patients With In-Frame or Out-of-Frame DMD Deletions Pertinent to Exon 44 or 45","volume":"71","author":"Anthony","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2025.04.038_bib43","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1002\/humu.21114","article-title":"Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort","volume":"30","author":"Flanigan","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2025.04.038_bib44","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3233\/JND-230107","article-title":"Increase in Full-Length Dystrophin by Exon Skipping in Duchenne Muscular Dystrophy Patients with Single Exon Duplications: An Open-label Study","volume":"11","author":"Nicolau","year":"2024","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.04.038_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244215","article-title":"Detailed genetic and functional analysis of the hDMDdel52\/mdx mouse model","volume":"15","author":"Yavas","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.04.038_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2023.07.155","article-title":"P28 The antisense oligonucleotide BMN 351 durably ameliorates dystrophic phenotypes in a mouse model of exon 51\u2013skip-amenable Duchenne muscular dystrophy","volume":"33","author":"Porco","year":"2023","journal-title":"Neuromuscul. Disord"},{"key":"10.1016\/j.ymthe.2025.04.038_bib47","article-title":"331P A Phase 1\/2 clinical trial of the antisense oligonucleotide BMN 351 now actively recruiting boys with exon 51\u2013skip-amenable Duchenne muscular dystrophy","volume":"43","author":"Duis","year":"2024","journal-title":"[Conference Abstract]. Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.04.038_bib48","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nbt.3948","article-title":"Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides","volume":"35","author":"Iwamoto","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.04.038_bib49","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1093\/nar\/gkac018","article-title":"Control of backbone chemistry and chirality boost oligonucleotide splice switching activity","volume":"50","author":"Kandasamy","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.04.038_bib50","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.nmd.2023.07.145","article-title":"P18 WVE-N531 with PN backbone modification significantly enhances drug concentrations in heart, diaphragm, and skeletal muscles in non-human primates","volume":"33","author":"Hart","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.04.038_bib54","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JND-160146","article-title":"Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides","volume":"3","author":"Goyenvalle","year":"2016","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.04.038_bib55","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1126\/science.2662404","article-title":"The Molecular Basis of Muscular Dystrophy in the mdx Mouse: a Point Mutation","volume":"244","author":"Sicinski","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.04.038_bib56","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nm.3765","article-title":"Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers","volume":"21","author":"Goyenvalle","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.04.038_bib57","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.3390\/ijms23084270","article-title":"Antisense Oligonucleotides Conjugated with Lipophilic Compounds: Synthesis and In Vitro Evaluation of Exon Skipping in Duchenne Muscular Dystrophy","volume":"23","author":"Marchesi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.04.038_bib58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/nar\/gkab1199","article-title":"Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides","volume":"50","author":"Relizani","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.04.038_bib59","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1006\/bbrc.1997.7328","article-title":"Targeted Disruption of Exon 52 in the Mouse Dystrophin Gene Induced Muscle Degeneration Similar to That Observed in Duchenne Muscular Dystrophy","volume":"238","author":"Araki","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2025.04.038_bib60","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.omtn.2023.03.009","article-title":"Partial restoration of brain dystrophin by tricyclo-DNA antisense oligonucleotides alleviates emotional deficits in mdx52 mice","volume":"32","author":"Saoudi","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.04.038_bib61","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1021\/nn4057269","article-title":"Cell-Penetrating Peptides: Design, Synthesis, and Applications","volume":"8","author":"Copolovici","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.ymthe.2025.04.038_bib62","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1093\/hmg\/ddn293","article-title":"Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function","volume":"17","author":"Yin","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2025.04.038_bib63","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.omtn.2022.08.019","article-title":"A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate morpholino oligomers in mdx mice","volume":"30","author":"Gan","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.04.038_bib64","series-title":"Presentation at the OTS Congress","article-title":"Development of Quantitative In Vitro Patient-Derived Cellular Models of Duchenne Muscular Dystrophy to Evaluate Peptide Phosphorodiamidate Morpholino Oligomers","author":"Erickson","year":"2020"},{"key":"10.1016\/j.ymthe.2025.04.038_bib65","series-title":"Poster P.6, Muscular Dystrophy Assoc. Virtual Clin. Scientific Conference","article-title":"Biological Efficacy of the Peptide-Conjugated Phosphorodiamidate Morpholino Oligomer SRP-5051 in Preclinical Models of Duchenne Muscular Dystrophy","author":"Hadcock","year":"2021"},{"key":"10.1016\/j.ymthe.2025.04.038_bib66","series-title":"Presentation at the OTS Congress","article-title":"Evaluation of the Pharmacokinetic and PharmacodynamicProperties of SRP-5051 in Nonhuman Primates After Single and Multiple Doses","author":"Shadid","year":"2020"},{"key":"10.1016\/j.ymthe.2025.04.038_bib67","series-title":"Clinical Update: MOMENTUM Multiple Ascending Dose Study of SRP 5051 for Duchenne Muscular Dystrophy","year":"2020"},{"key":"10.1016\/j.ymthe.2025.04.038_bib70","series-title":"Presentation at the Muscular Dystrophy Association Clinical & Scientific Conference","article-title":"Phase 2 Multiple Ascending Dose Study of SRP-5051 PPMO in Patients With DMD Amenable to Exon 51 Skipping: Part A Results","author":"Campbell","year":"2022"},{"key":"10.1016\/j.ymthe.2025.04.038_bib71","series-title":"Clinical Update: MOMENTUM (Study SRP-5051-201, Part B). [Sarepta Therapeutics update]","article-title":"Patients can\u2019t wait for the next breakthrough in medical research. So neither will we","author":"Ingram","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.038_bib74","series-title":"Poster P.248, OTS Congress","article-title":"Mechanistic characterization of enhanced delivery oligonucleotide (EDO) platform","author":"Emanuelson","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.038_bib75","series-title":"Poster 242, Muscular Dystrophy Association clinical and scientific conference","article-title":"Nonclinical Data Demonstrate the Potential of the Enhanced Delivery Oligonucleotide (EDO) PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy","author":"Holland","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.038_bib76","series-title":"Poster presented at OTS Congress","article-title":"Nonclinical in vitro and in vivo data demonstrated low immunogenicity risk and favorable profiles of PGN-EDO51 for the treatment of DMD","author":"Garg","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.038_bib77","series-title":"Poster S17., Muscular Dystrophy Assoc. Clin. scientific conference","article-title":"Single- and Repeat-Dose Nonclinical Data for PGN-EDO51 Demonstrated Potential for the Treatment of Duchenne Muscular Dystrophy (DMD)","author":"Holland","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.038_bib78","series-title":"[PepGen update]","article-title":"Advancing the Use of Peptide-Conjugated Oligonucleotides to Target Neuromuscular Disorders: Enhanced Delivery Oligonucleotides for DMD and DM1","author":"McArthur","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.038_bib79","series-title":"Poster 403P, 29th Annu. Congress World Muscle Society","article-title":"CONNECT1-EDO51: A 12-week open-label Phase 2 study to evaluate PGN-EDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping","author":"Mellion","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.038_bib82","series-title":"Poster M151, Muscular Dystrophy Assoc. Clin. scientific conference","article-title":"CONNECT2-EDO51: A Phase 2 placebo-controlled study to evaluate PGNEDO51 safety and efficacy in people with Duchenne amenable to exon 51 skipping","author":"Mellion","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.038_bib84","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1261\/rna.079507.122","article-title":"Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?","volume":"29","author":"Dowdy","year":"2023","journal-title":"RNA"},{"key":"10.1016\/j.ymthe.2025.04.038_bib85","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1021\/bi5004102","article-title":"Early Endosomal Escape of a Cyclic Cell-Penetrating Peptide Allows Effective Cytosolic Cargo Delivery","volume":"53","author":"Qian","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.ymthe.2025.04.038_bib86","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.omtn.2023.06.022","article-title":"The endosomal escape vehicle platform enhances delivery of oligonucleotides in preclinical models of neuromuscular disorders","volume":"33","author":"Li","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.04.038_bib87","doi-asserted-by":"crossref","first-page":"104441.304","DOI":"10.1016\/j.nmd.2024.07.313","article-title":"433P Therapeutic potential of ENTR-601-44, an Endosomal Escape Vehicle (EEVTM) - Oligonucleotide Conjugate for the treatment of exon 44 skip amenable DMD","volume":"43","author":"Oldham","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.04.038_bib91","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/BF01116187","article-title":"Specific membrane receptors for diferric-transferrin in cultured rat skeletal myocytes and chick-embryo cardiac myocytes","volume":"1","author":"Fava","year":"1981","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ymthe.2025.04.038_bib92","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-Drug Conjugates in Cancer Therapy","volume":"64","author":"Sievers","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ymthe.2025.04.038_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2016.06.036","article-title":"Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles","volume":"237","author":"Sugo","year":"2016","journal-title":"J. Control Release"},{"key":"10.1016\/j.ymthe.2025.04.038_bib94","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2025.04.038_bib95","series-title":"Poster presented Am. Soc. Gene Cell Ther. Annu. Meeting","article-title":"Targeted Delivery of ASOs Demonstrates Potential to Treat Duchenne Muscular Dystrophy","author":"Yao","year":"2020"},{"key":"10.1016\/j.ymthe.2025.04.038_bib96","doi-asserted-by":"crossref","first-page":"11401","DOI":"10.1093\/nar\/gkac641","article-title":"Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice","volume":"50","author":"Desjardins","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.04.038_bib97","series-title":"Presentation Muscle Study Group Annu. Scientific Meeting","article-title":"FORCETMPlatform Delivers Exon Skipping PMO, Leads to Durable Increases in Dystrophin Protein in mdxMice and Is Well Tolerated in NHPs","author":"Beskrovnaya","year":"2021"},{"key":"10.1016\/j.ymthe.2025.04.038_bib98","series-title":"Poster 225P, 29th Annual Congress of the World Msucle Society","article-title":"Initial Data from the DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping","author":"De Waele","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.038_bib99","article-title":"Achieving the Promise of Force to Deliver for Patients","author":"Cox","year":"2024","journal-title":"[Dyne Ther. update]"},{"key":"10.1016\/j.ymthe.2025.04.038_bib100","series-title":"Presentation at the 2024 American Academy of Neurology Annual Meeting","article-title":"Initial Data from the DELIVER Trial of DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping","author":"Shieh","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.038_bib101","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/nar\/gkad415","article-title":"Targeted tissue delivery of RNA therapeutics using antibody\u2013oligonucleotide conjugates (AOCs)","volume":"51","author":"Malecova","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.04.038_bib102","author":"Boyce"},{"key":"10.1016\/j.ymthe.2025.04.038_bib103","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3233\/JND-170218","article-title":"Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR\/Cas9 Gene Editing Therapy","volume":"4","author":"Young","year":"2017","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.04.038_bib104","series-title":"Poster P.198, 27th Annual Congress of the World Muscle Society","article-title":"AOC 1044 Mediated Exon 44 Skipping and Restoration of Dystrophin Protein in Cynomolgus Monkeys and DMD Patient Derived Myotubes","author":"Karamanlidis","year":"2022"},{"key":"10.1016\/j.ymthe.2025.04.038_bib105","series-title":"Poster 240, Muscular Dystrophy Association Clinical and Scientific Conference","article-title":"AOC 1044: An Antibody Oligonucleotide Conjugate as a Novel Therapeutic Approach for DMD Patients Amenable to Exon 44 Skipping","author":"Etxaniz","year":"2023"},{"key":"10.1016\/j.ymthe.2025.04.038_bib106","series-title":"Poster VP43, 28th Annual Congress of the World Muscle Society","article-title":"Phase 1\/2 Trial Evaluating AOC 1044 in Healthy Volunteers and Participants with DMD Mutations Amenable to Exon 44 Skipping (DMD44): EXPLORE44TM Trial Design","author":"Stahl","year":"2023"},{"key":"10.1016\/j.ymthe.2025.04.038_bib107","series-title":"Poster M181, Muscular Dystrophy Association Clinical and Scientific Conference","article-title":"AOC 1044 as a Novel Therapeutic Approach for DMD Patients Amenable to Exon 44 Skipping: EXPLORE44TM Phase 1\/2 Healthy Volunteer Data","author":"Stahl","year":"2024"},{"key":"10.1016\/j.ymthe.2025.04.038_bib109","article-title":"Delivering on the RNA Revolution","year":"2024","journal-title":"[Avidity Biosciences update]"},{"key":"10.1016\/j.ymthe.2025.04.038_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2023.102034","article-title":"Exon 44 skipping in Duchenne muscular dystrophy: NS-089\/NCNP-02, a dual-targeting antisense oligonucleotide","volume":"34","author":"Watanabe","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.04.038_bib112","article-title":"Phase 1\/2 trial of brogidirsen: Dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy","volume":"6","author":"Komaki","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2025.04.038_bib114","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3233\/JND-180357","article-title":"Report of a TREAT-NMD\/World Duchenne Organisation Meeting on Dystrophin Quantification Methodology","volume":"6","author":"Aartsma-Rus","year":"2019","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ymthe.2025.04.038_bib115","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1096\/fj.13-232025","article-title":"DMD transcript imbalance determines dystrophin levels","volume":"27","author":"Spitali","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.ymthe.2025.04.038_bib116","doi-asserted-by":"crossref","first-page":"16456","DOI":"10.1073\/pnas.1910456117","article-title":"Premature termination codons in the DMD gene cause reduced local mRNA synthesis","volume":"117","author":"Garc\u00eda-Rodr\u00edguez","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ymthe.2025.04.038_bib117","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13395-024-00360-4","article-title":"Golodirsen restores DMD transcript imbalance in Duchenne Muscular Dystrophy patient muscle cells","volume":"14","author":"Rossi","year":"2024","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.ymthe.2025.04.038_bib118","doi-asserted-by":"crossref","first-page":"7530","DOI":"10.1038\/s41467-024-48204-5","article-title":"Heteroduplex oligonucleotide technology boosts oligonucleotide splice switching activity of morpholino oligomers in a Duchenne muscular dystrophy mouse model","volume":"15","author":"Hasegawa","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.04.038_bib119","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/humu.20428","article-title":"Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy","volume":"28","author":"B\u00e9roud","year":"2007","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2025.04.038_bib120","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2014.76","article-title":"Long-Term Efficacy of Systemic Multiexon Skipping Targeting Dystrophin Exons 45\u201355 With a Cocktail of Vivo-Morpholinos in Mdx52 Mice","volume":"4","author":"Echigoya","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.04.038_bib121","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.ymthe.2019.07.012","article-title":"Exons 45\u201355 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene","volume":"27","author":"Echigoya","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.04.038_bib122","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/965631","article-title":"Understanding the Process of Fibrosis in Duchenne Muscular Dystrophy","volume":"2014","author":"Kharraz","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ymthe.2025.04.038_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1180980","article-title":"Satellite cell contribution to disease pathology in Duchenne muscular dystrophy","volume":"14","author":"Kodippili","year":"2023","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ymthe.2025.04.038_bib124","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with Duchenne muscular dystrophy","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2025.04.038_bib125","article-title":"Histone deacetylase inhibition with givinostat: a multi-targeted mode of action with the potential to halt the pathological cascade of Duchenne muscular dystrophy","volume":"12","author":"Aartsma-Rus","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ymthe.2025.04.038_bib126","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.omtn.2022.11.017","article-title":"Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice","volume":"30","author":"Bizot","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.04.038_bib127","series-title":"Handbook of Clinical Neurology Muscular Dystrophies.","first-page":"81","article-title":"Chapter 5 - The collagen VI-related myopathies: Ullrich congenital muscular dystrophy and Bethlem myopathy","author":"B\u00f6nnemann","year":"2011"},{"key":"10.1016\/j.ymthe.2025.04.038_bib128","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1089\/hum.2012.109","article-title":"Antisense-Induced Messenger Depletion Corrects a COL6A2 Dominant Mutation in Ullrich Myopathy","volume":"23","author":"Gualandi","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.038_bib129","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124403","article-title":"A recurrent COL6A1 pseudoexon insertion causes muscular dystrophy and is effectively targeted by splice-correction therapies","volume":"4","author":"Bolduc","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2025.04.038_bib130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.omtn.2020.05.029","article-title":"Exon-Skipping Oligonucleotides Restore Functional Collagen VI by Correcting a Common COL6A1 Mutation in Ullrich CMD","volume":"21","author":"Aguti","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.04.038_bib131","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41525-021-00266-w","article-title":"Lamin A\/C missense variants: from discovery to functional validation","volume":"6","author":"Lazarte","year":"2021","journal-title":"Npj Genom. Med."},{"key":"10.1016\/j.ymthe.2025.04.038_bib132","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev-pathol-042220-034240","article-title":"Molecular Pathology of Laminopathies","volume":"17","author":"Shin","year":"2022","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ymthe.2025.04.038_bib133","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/gt.2015.8","article-title":"Ameliorating pathogenesis by removing an exon containing a missense mutation: a potential exon-skipping therapy for laminopathies","volume":"22","author":"Scharner","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.04.038_bib134","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.04.038_bib135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/nat.2021.0035","article-title":"Individualized Therapeutics Development for Rare Diseases: The Current Ethical Landscape and Policy Responses","volume":"32","author":"Bateman-House","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2025.04.038_bib136","doi-asserted-by":"crossref","first-page":"W193","DOI":"10.1093\/nar\/gkab442","article-title":"eSkip-Finder: a machine learning-based web application and database to identify the optimal sequences of antisense oligonucleotides for exon skipping","volume":"49","author":"Chiba","year":"2021","journal-title":"Nucleic Acids Res."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162500317X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162500317X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:03:29Z","timestamp":1780535009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162500317X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":119,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S152500162500317X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.038","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical applications of exon-skipping antisense oligonucleotides in neuromuscular diseases","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.04.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society of Gene and Cell Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}